Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) Operating Expenses (2017 - 2021)

Cogent Biosciences has reported Operating Expenses over the past 5 years, most recently at $25.6 million for Q4 2021.

  • Quarterly results put Operating Expenses at $25.6 million for Q4 2021, up 123.81% from a year ago — trailing twelve months through Dec 2021 was $75.6 million (down 16.12% YoY), and the annual figure for FY2025 was $333.4 million, up 20.81%.
  • Operating Expenses for Q4 2021 was $25.6 million at Cogent Biosciences, up from $19.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for COGT hit a ceiling of $57.5 million in Q3 2020 and a floor of $7.9 million in Q1 2017.
  • Median Operating Expenses over the past 5 years was $12.8 million (2018), compared with a mean of $15.0 million.
  • Biggest five-year swings in Operating Expenses: soared 340.49% in 2020 and later tumbled 65.54% in 2021.
  • Cogent Biosciences' Operating Expenses stood at $9.0 million in 2017, then surged by 42.27% to $12.8 million in 2018, then increased by 1.87% to $13.0 million in 2019, then dropped by 12.2% to $11.5 million in 2020, then surged by 123.81% to $25.6 million in 2021.
  • The last three reported values for Operating Expenses were $25.6 million (Q4 2021), $19.8 million (Q3 2021), and $17.3 million (Q2 2021) per Business Quant data.